Sotalol: a novel beta-blocker with class III anti-arrhythmic activity.
Initially synthesized in 1960, sotalol is a novel beta-adrenoreceptor blocking agent that also possesses class III anti-arrhythmic properties. The drug's ability to lengthen repolarization and prolong effective refractory periods in all cardiac tissues in addition to its beta-blocking effects make sotalol an attractive agent for use in a variety of supraventricular and ventricular arrhythmias.
Leibowitz
D
D
Department of Medicine, Mount Sinai Medical Center, New York, New York.
D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D006352:Heart Ventricles; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D017202:Myocardial Ischemia / Q000188:drug therapy; D013015:Sotalol / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D013617:Tachycardia, Supraventricular / Q000188:drug therapy; D017180:Tachycardia, Ventricular / Q000188:drug therapy
D013015:Sotalol